Purpose: The aim of this study was to determine the survival rate of short implants that were placed in a residency program. In addition, the potential influence of diabetes, smoking, sinus grafting, guided bone regeneration, and implant type on survival was analyzed.
Methods: Through a retrospective chart review, patient information and parameters for short implants being equal or less than 10 mm and regular implants being more than 10 mm were collected. The cumulative survival rate and implant and patient information from 213 consecutively placed implants from May 2002 through October 2011 were analyzed.
Results: The average survival time for short implants was 47.3 months, with a range of 6 to 141 months. The implant survival rate was 95.77% for short implants, which was not statistically significant from the regular implants. Smoking had a statistically significant negative effect on the survival rate of short implants. No statistical differences were found with implant survival rates for other factors.
Conclusion: It can be concluded that short implants can be predictably placed in the mouth with a high survival rate and that smoking has a negative influence on the survival rate of the short implants.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ID.0000000000000229 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advancing precision medicine in esophageal squamous cell carcinoma using patient-derived organoids.
J Transl Med
December 2024
Department of Precision Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, China.
Background: Patient-derived organoids (PDOs) represent a promising approach for replicating the characteristics of original tumors and facilitating drug testing for personalized treatments across diverse cancer types. However, clinical evidence regarding their application to esophageal cancer remains limited. This study aims to evaluate the efficacy of implementing PDOs in clinical practice to benefit patients with esophageal squamous cell carcinoma (ESCC).
View Article and Find Full Text PDFA clinical analysis and literature review of eleven cases with primary pulmonary angiosarcoma.
BMC Cancer
December 2024
National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Objective: The aim of this study is to explore the clinicopathological features, radiographic manifestations, treatment options, and prognosis of primary pulmonary angiosarcoma (PPAS).
Method: We summarized and analyzed the clinical data of 11 patients with primary pulmonary angiosarcoma treated at the First Affiliated Hospital of Guangzhou Medical University between January 2018 and January 2024. A retrospective analysis was conducted in conjunction with a review of the relevant literature.
Programmed cell death 1 inhibitor alone or combined with chemotherapy for patients with locally advanced or metastatic urothelial carcinoma: a single-center experience.
BMC Urol
December 2024
Department of Radiation Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Background: Immune checkpoint inhibitors (ICIs) alone or in combination with standard chemotherapy for advanced urothelial carcinoma (UC) have been tested as first-line treatment in clinical trials. This study aimed to evaluate the clinical outcomes of programmed cell death 1 (PD-1) inhibitor alone or combined with chemotherapy for patients with locally advanced or metastatic UC in a real world clinical care setting, and sought to identify prognostic factors for overall survival (OS).
Methods: A retrospective, real-world study involving 35 locally advanced or metastatic UC patients treated with PD-1 inhibitor alone or in combination with chemotherapy was conducted.
Analysis of the implementation value of abdominal B-ultrasound combined with cervical cerclage in the prevention and treatment of late recurrent spontaneous abortion.
BMC Pregnancy Childbirth
December 2024
Ultrasound Department, Ganzhou Maternal and Child Health Hospital, No. 25, Nankang Road, Zhanggong District, Ganzhou City, Jiangxi Province, 341000, China.
Objective: To study the implementation value of abdominal B-ultrasound combined with cervical cerclage in the prevention and treatment of recurrent late abortion.
Methods: From October 2020 to December 2023, 196 pregnant patients who had a history of late abortions at our institution were chosen. They were divided into groups based on the treatments used.
Combination of Compound Kushen injection with first-line treatment versus first-line treatment alone for advanced colorectal cancer: a study protocol for a multicenter, openlabel, randomized controlled trial.
BMC Complement Med Ther
December 2024
Oncology Department, Guang'anmen Hospital, China, Academy of Chinese Medical Sciences, Beixian Pavilion, No.5, Xicheng District, Beijing, China.
Background: The treatment of advanced colorectal cancer (CRC) has progressed slowly, with chemotherapy combined with targeted therapy being the first-line treatment for the disease, but the improvement in efficacy is not satisfactory. Compound Kushen injection (CKI) is one of the representative drugs of anti-cancer Chinese herbal injection drugs, which has been widely used in the adjunct treatment of cancer in China. The aim of this trial is to evaluate the efficacy and safety of CKI combined with first-line treatment of advanced CRC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!